Program Materials

Review Papers

• Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation (Lingvay et al, Lancet 2022)
• Reassessing Human Adipose Tissue (Cypess, NEJM 2022)
• Ethnic differences in adiposity and diabetes risk - insights from genetic studies (Yaghootkar et al, J Intern Med 2020)
• Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm (Abdul-Ghani & Defronzo, Diabetes Care 2017)
• How May GIP Enhance the Therapeutic Efficacy of GLP-1? (Samms et al, Trends Endocrinol Metab 2020)
• Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins' (Skow et al, Diabetes Obes Metab 2016)

Study Publications

• Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study
• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Rosenstock et al, Lancet. 2021)
• Ethnic differences in adiposity and diabetes risk - insights from genetic studies (Yaghootkar et al, J Intern Med 2020)
• Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial (Ludvik et al, Lancet 2021)
• Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial (Del Prato et al, Lancet 2021)
• Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial (Dahl et al, JAMA 2022)
• Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, Jastreboff et al, N Engl J Med 2022)

Guidelines

• Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update (Diabetes Canada)
• Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update — The User’s Guide
• Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)